Sidney Kimmel Medical College

Name

Sidney Kimmel Medical College

Legal name

Thomas Jefferson University

Website

https://jefferson.edu

Company type

Private

Founded year

1824

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Medical Education

NAICS

Colleges, Universities, and Professional Schools (6113), Colleges, Universities, and Professional Schools (611310)

SIC

Services-Educational Services (8200), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Theological Universities & Pontifical Universities (EDAHAKAD), Health Science & Medical STEM Programs (Pre-Med, Public Health) (EDAMABAJ), Healthcare Clinical Professions (CME/CE for Nurses, Allied Health, Pharmacy) (EDAAALAC)

Keywords

• Medical education
• MD degree program
• Residency training
• Biomedical research
• Medical school

Headquarters

HQ city

Philadelphia

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Distribution channels4 records

Marketing channels5 records

Core offering

Sidney Kimmel Medical College is the medical school of Thomas Jefferson University, providing undergraduate medical education leading to the MD degree, residency and fellowship training, PhD and master's biomedical research training, and continuing medical education for practicing physicians. The college conducts federally funded biomedical and clinical research and supports clinical care delivery through the Jefferson Health system, while commercializing medical technologies through Jefferson Ventures.

Product overview

Sidney Kimmel Medical College (SKMC) is the medical school component of Thomas Jefferson University, functioning as both an educational institution and healthcare research organization. The college offers undergraduate programs (BS in Biology), graduate programs (PhD in Cell Biology & Regenerative Medicine, MS in Business Analytics, MS in Data Analytics, MS in Computational Biology & Medicine), professional certificates (AI in Health Analytics Leadership), and medical education. SKMC also develops and licenses medical technologies including a smartphone-integrated epinephrine autoinjector through Jefferson Ventures. AI capabilities include predictive analytics for radiation therapy outcomes, process automation for clinical workflows, and generative AI applications in nursing education and fashion design. The institution is affiliated with Jefferson Health, providing clinical care services.

Differentiator

Problem solved

Functional benefit

Products and services

• Sidney Kimmel Medical College MD Degree Program World-renowned medical education program at Thomas Jefferson University offering the Doctor of Medicine (MD) degree, with more than 31,000 degrees awarded since 1824 and the largest living alumni physician base of any U.S. medical school. Aspiring medical students apply through the AMCAS/NRMP process.
• Pathology Residency Program Four-year ACGME-accredited residency training program in pathology with focus on laboratory medicine and pathology, directed by Joanna Chan, MD, FCPP, FCAP. Provides specialty training to resident physicians.
• Transfusion Medicine Fellowship Program Fellowship program providing career development training to prepare qualified physicians for leadership positions in transfusion medicine, directed by Angelica Vivero, MD.
• Cytopathology Fellowship Program Fellowship program training fellows to become competent cytopathologists capable of practice in academic or private practice settings, directed by Allison Goldberg, MD.
• Hematopathology Fellowship Program Fellowship program with training in all areas of hematopathology including bone marrow and lymph node diagnosis, directed by Jerald Gong, MD.
• PhD in Cell Biology & Regenerative Medicine PhD graduate program providing training in molecular and cellular biology, tissue engineering, genetic animal models, advanced imaging techniques, bioinformatics and computational modeling for therapeutic strategies. Directed by Ryan Tomlinson, PhD.
• Artificial Intelligence (AI) in Health Analytics Leadership Advanced Practice Certificate Advanced practice certificate program focused on AI applications in health analytics, part of the College of Population Health offerings and the university's AI/data analytics initiative.
• AI-Driven Radiation Oncology Risk Prediction Service Department of Radiation Oncology clinical AI capability at SKMC using artificial intelligence to predict patient risk of side effects from radiation therapy, enabling proactive identification of vulnerable patients and personalized treatment plans.
• Genomic Pathology Clinical Laboratory Molecular biology-based diagnostic testing service offering sequencing, quantitative PCR, FISH, karyotyping, and targeted next-generation sequencing pan cancer panel with expert bioinformatics analysis. Technical Director: Zi-Xuan (Zoe) Wang, PhD.
• Jefferson Ventures Technology Commercialization & Licensing Technology commercialization arm of Jefferson that manages 1,434 issued patents, 700+ active patents, 380 patents licensed under active licenses, and has launched 25+ startups which together have raised $1.27 billion. Supports technology transfer, intellectual property protection and commercialization sections of grant proposals.

Quantifiable outcome

• More than 31,000 medical degrees awarded since 1824
• +4 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

14 partnerships are on record, tiered core and minor.

• State of Delaware / Delaware Medical School ConsortiumcoreStrategic or Co-development Partner · 2 June 2026Delaware partnered with Thomas Jefferson University to establish a regional campus of Sidney Kimmel Medical College in Delaware, creating the state's first four-year medical school. Delaware is currently one of only three states without an M.D. or D.O.-granting institution. The Delaware Medical School Consortium will enable students to complete their entire medical education in-state while building a physician pipeline for communities. The project is supported by a $157.4 million federal grant from the Centers for Medicare and Medicaid Services under the Rural Health Transformation Program.
• Sempresto, Inc.coreOEM/ Whitelabel/ Licensing Partner · 10 December 2025Thomas Jefferson University and Sempresto, Inc. announced a broad strategic partnership expanding upon Sempresto's existing exclusive license from Jefferson for groundbreaking platform technology invented by Dr. Edmund Pribitkin. Sempresto is commercializing a smartphone-integrated epinephrine autoinjector that addresses the gap in emergency care by ensuring lifesaving medications are always on hand. Nearly two-thirds of patients experiencing severe allergic reactions arrive at the Emergency Department without having received epinephrine beforehand. The device is designed to eliminate common barriers to proper utilization and significantly improve patient access to rescue medicine.
• Imvax, Inc.coreStrategic or Co-development PartnerClinical-stage biotechnology company developing personalized, tumor-derived immunotherapies invented by Jefferson researchers and clinicians. In December 2025, the company announced results from its Phase IIb trial of IGV-001 to treat newly diagnosed glioblastoma multiforme, the deadliest of brain cancers. IGV-001 increased median overall survival by 6.3 months or 45% over standard of care. Imvax has raised over $235 million in funding across multiple rounds.
• Xilio TherapeuticscoreStrategic or Co-development PartnerClinical-stage biopharmaceutical company formed around technology for tumor-activated oncology therapies designed to treat cancer while minimizing severe systemic side effects, licensed from Jefferson and the City of Hope. Company completed IPO in October 2021 and raised significant capital through multiple private funding rounds including Series A co-led by F-Prime Capital and Atlas Venture, $100.5M Series B led by Takeda Ventures, and $95M Series C led by Rock Springs Capital.
• Veralox TherapeuticscoreStrategic or Co-development PartnerClinical-stage biotechnology company focused on developing first-in-class therapeutics targeting underlying pathologies of serious immuno-inflammatory diseases. Co-developed through multi-institutional collaboration of Jefferson, NIH, Eastern Virginia Medical School and University of California. Lead drug candidate VLX-1005 is in Phase 2 clinical study for heparin-induced thrombocytopenia (HIT), granted Fast Track and Orphan Drug designations by FDA. Raised over $40M across multiple rounds.
• ImmunomecoreStrategic or Co-development PartnerClinical-stage oncology company developing antibody-based therapies that target novel antigen-antibody pairs identified from patients' immune responses to their own tumors. Company originated from technology jointly created at Thomas Jefferson University and MIT Whitehead Institute. Secured Series A funding in 2016 and 2017, began trading on Nasdaq in October 2020.
• RTM Vital SignsminorStrategic or Co-development PartnerClinical-stage Jefferson spinout developing wearable devices that use artificial intelligence and acoustic technology to provide continuous, real-time monitoring of patient vital signs. Received Fast Track Designation from FDA in 2020 and FDA 510(k) clearance in July 2025 for first-generation Respiratory Monitoring System.
• Bound TherapeuticsminorStrategic or Co-development PartnerPreclinical-stage biotechnology company advancing Jefferson-discovered nucleic acid-based therapeutics RNA inhibitors for triple negative breast cancer towards clinic. Pipeline has expanded to include lungs, colon, prostate and brain cancers.
• KOP TherapeuticsminorStrategic or Co-development PartnerPreclinical-stage biotechnology company focused on development of novel RNA-based cancer therapies discovered by Jefferson researchers. As of October 2025, KOP has validated its AON therapy in prostate, breast, brain and ovarian cancer cells.
• NuView Life SciencesminorStrategic or Co-development PartnerClinical-stage radiopharmaceutical company developing next-generation products for both diagnosis and treatment of cancer based on technology invented at Jefferson. Proprietary platform NV-VPAC1 targets vasoactive peptide type 1 receptor for diagnosis and treatment of prostate, breast, brain and pancreatic cancers.
• BioVaxysminorStrategic or Co-development PartnerClinical-stage biopharmaceutical company developing technology based on pioneering work of Jefferson researchers. Multiple product candidates in pipeline ranging from Phase II clinical trials to preclinical development, focusing on cancer immunotherapies, infectious diseases, and allergies.
• Mayo CliniccoreStrategic or Co-development PartnerNational leaders in asthma/receptor biology collaborating as part of the NIH P01 grant investigative team led by Raymond B. Penn, PhD at Thomas Jefferson University. Y.S. Prakash, MD, PhD from Mayo Clinic contributes to the research program focused on exploiting emerging ideas in G protein-coupled receptor biology and pharmacology to treat asthma.
• Rutgers UniversitycoreStrategic or Co-development PartnerNational leaders in asthma/receptor biology collaborating as part of the NIH P01 grant investigative team. Reynold Panettieri, MD from Rutgers University contributes to the multidisciplinary research project.
• Stanford UniversitycoreStrategic or Co-development PartnerNational leaders in asthma/receptor biology collaborating as part of the NIH P01 grant investigative team. Brian Kobilka, PhD from Stanford University contributes to the research program.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Georgetown University School of Medicine: Private Jesuit-affiliated medical school of similar standing and Tier 2/3 U.S. News positioning. Comparable as a private M.D.-granting institution with research intensity, clinical training partnerships, and similar applicant profile.
• Tufts University School of Medicine: Private medical school of comparable tier and historical standing. Directly comparable as a private M.D.-granting institution with NIH-funded research portfolio and an emphasis on primary care and translational research.
• Lewis Katz School of Medicine at Temple University: Philadelphia-based medical school training M.D.s in the same metropolitan market. Directly comparable as a competing medical school with a comparable clinical-emphasis mission and similar applicant demographics.
• University of Pittsburgh School of Medicine: Major research-intensive public medical school with comparable NIH funding scale and translational research output. Comparable as a competitor for NIH grants, faculty recruitment, and clinical research partnerships.
• Case Western Reserve University School of Medicine: Private research-oriented medical school of comparable size and standing. Comparable as a private M.D. program with a strong NIH research base, technology-transfer activity, and an emphasis on biomedical innovation.
• Perelman School of Medicine (University of Pennsylvania): Elite private Ivy League medical school located in Philadelphia alongside SKMC. Directly comparable as a Tier 1 private M.D.-granting institution serving similar student demographics with affiliated health system, major NIH research portfolio, and spinout activity.
• Drexel University College of Medicine: Private Philadelphia-based medical school with similar student profile and tier-level ranking. Directly comparable as a competing regional private M.D. program drawing from the same applicant pool and labor market.
• Emory University School of Medicine: Private research-intensive medical school in the same competitive tier as SKMC. Comparable in NIH-funded research scale, affiliated health system, and ability to spin out biotechnology companies from faculty discoveries.

Broad incumbents

• Weill Cornell Medicine: Elite Ivy League private medical school with significantly higher U.S. News ranking. Comparable as a benchmark for SKMC's aspirational positioning in research output, residency match rates, and NIH funding.
• Mayo Clinic Alix School of Medicine: Elite private medical school integrated with a top-ranked hospital system. Comparable as a research-active M.D. program and as a current SKMC research collaborator on the NIH P01 asthma program.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/tjuhospital
• YouTubeyoutube.com/JeffersonUniv
• Facebookfacebook.com/JeffersonUniv
• LinkedInlinkedin.com/company/sidney-kimmel-medical-college
• Instagraminstagram.com/JeffersonUniv

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sidney Kimmel Medical College